IL3RA and acute myeloid leukemia: Severe cytokine release syndrome and capillary leak syndrome were described in the patients with AML and BPDCN who were treated with an anti-CD123 “universal” CART (UCART123) as part of Phase 1 clinical trials (NCT03203369, NCT03190278 respectively).